Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases
Open Access
- 7 September 2021
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 9 (9) , e04574
Abstract
Immune checkpoint inhibitor‐induced diabetes mellitus is a rare immune‐related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes.Keywords
This publication has 40 references indexed in Scilit:
- Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinomaAnnals of Oncology, 2016
- Case of type 1 diabetes associated with less‐dose nivolumab therapy in a melanoma patientThe Journal of Dermatology, 2016
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 DiabetesThe Tohoku Journal of Experimental Medicine, 2016
- Tumor Immunotherapy Directed at PD-1New England Journal of Medicine, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) MiceJournal of Experimental Medicine, 2003
- Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic PatientsDiabetes Care, 2003